Bridgebio Pharma (BBIO)
NASDAQ:BBIO
Want to see BBIO full AI Analyst Report?
BBIO Stock Chart & Stats
$76.75
-$0.10(-0.35%)
At close: 4:00 PM EST
$76.75
-$0.10(-0.35%)
Day’s Range― - ―
52-Week Range$35.15 - $84.94
Previous CloseN/A
Volume379.31K
Average Volume (3M)2.96M
Market Cap
$12.51B
Enterprise Value$15.48B
Total Cash (Recent Filing)$940.19M
Total Debt (Recent Filing)$3.38B
Price to Earnings (P/E)―
Beta0.67
Next Earnings
Jul 30, 2026EPS Estimate
-0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.75
Shares Outstanding195,861,240
10 Day Avg. Volume2,592,631
30 Day Avg. Volume2,955,489
Financial Highlights & Ratios
PEG Ratio-0.65
Price to Book (P/B)-7.27
Price to Sales (P/S)30.05
P/FCF Ratio-33.75
Enterprise Value/Market Cap1.24
Enterprise Value/Revenue26.70
Enterprise Value/Gross Profit28.47
Enterprise Value/Ebitda-25.76
Forecast
1Y Price Target
$107.29Price Target Upside39.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
EPS Forecast (FY)-2.19
Revenue Forecast (FY)$963.02M
Bulls Say, Bears Say
Bulls Say
Commercial Revenue MomentumSustained, rapid Atruvio sales growth reflects durable product adoption and expanding frontline share in ATTR cardiomyopathy. A growing patient base and higher recurring specialty sales create a stable revenue platform that can support margin leverage, improved cash flow conversion, and reduced single-product concentration over months.
Very High Gross MarginsExceptionally high gross margins indicate attractive unit economics for commercialized therapies. With margin characteristics of specialty medicines, incremental revenue growth should flow substantially to operating leverage once SG&A/R&D growth moderates, improving the firm's ability to convert sales into durable operating profitability and cash generation.
Pipeline Regulatory ProgressPriority review for BBP-418 and multiple NDA filings (encaleret, infigratinib) represent structural pipeline de-risking and near-term approval optionality. Potential first-in-class approvals across rare diseases would diversify revenue beyond Atruvio, expand commercial franchises, and materially improve long-term revenue visibility and cash generation.
Bears Say
Heavy Cash BurnConsistent large negative operating and free cash flow requires ongoing external financing to fund R&D and launches. Even with recent cash builds, sustained negative FCF raises refinancing and dilution risk, constraining strategic optionality and forcing near-term capital markets activity unless profitability and cash flow swing positive.
Negative Shareholders' EquityA sizeable equity deficit reflects accumulated losses and weakens the capital base. Negative equity can limit financing choices, raise covenant and refinancing risks, and increase the cost of capital. Structurally this reduces financial flexibility for launches and pipeline investment over the coming quarters.
Rising Operating ExpensesInvestments to scale commercial infrastructure and prepare multiple launches have materially lifted SG&A and R&D, keeping operating losses elevated. Sustained high operating expense run-rate can delay achieving breakeven and increases the amount of external funding needed, pressuring margins and cash flow stability during rollout phases.
BridgeBio Pharma News
BBIO FAQ
What was Bridgebio Pharma’s price range in the past 12 months?
Bridgebio Pharma lowest stock price was $35.15 and its highest was $84.94 in the past 12 months.
What is Bridgebio Pharma’s market cap?
Bridgebio Pharma’s market cap is $12.51B.
When is Bridgebio Pharma’s upcoming earnings report date?
Bridgebio Pharma’s upcoming earnings report date is Jul 30, 2026 which is in 57 days.
How were Bridgebio Pharma’s earnings last quarter?
Bridgebio Pharma released its earnings results on May 07, 2026. The company reported -$0.84 earnings per share for the quarter, missing the consensus estimate of -$0.679 by -$0.161.
Is Bridgebio Pharma overvalued?
According to Wall Street analysts Bridgebio Pharma’s price is currently Undervalued.
Does Bridgebio Pharma pay dividends?
Bridgebio Pharma does not currently pay dividends.
What is Bridgebio Pharma’s EPS estimate?
Bridgebio Pharma’s EPS estimate is -0.59.
How many shares outstanding does Bridgebio Pharma have?
Bridgebio Pharma has 195,861,240 shares outstanding.
What happened to Bridgebio Pharma’s price movement after its last earnings report?
Bridgebio Pharma reported an EPS of -$0.84 in its last earnings report, missing expectations of -$0.679. Following the earnings report the stock price went down -0.089%.
Which hedge fund is a major shareholder of Bridgebio Pharma?
Currently, no hedge funds are holding shares in BBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BridgeBio Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$107.29 (39.80% Upside)
$107.29 (39.80% Upside)
Blogger Sentiment
Bullish
BBIO Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Bullish
Bullish news 79%
Bearish news 14%
Bearish news 14%
Technicals
SMA
Negative
20 days / 200 days
Momentum
80.14%
12-Months-Change
Fundamentals
Return on Equity
36.00%
Trailing 12-Months
Asset Growth
55.50%
Trailing 12-Months
Company Description
Bridgebio Pharma
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
BBIO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum (notably Atruvio revenue growth: $180.6M, +24% QoQ, +392% YoY), robust cash runway ($940.2M) and clear pipeline progress with active launch preparations (LGMD2I NDA, ADH1 patient ID, positive PROPEL‑3 for achondroplasia). Management emphasized clinical differentiation backed by real‑world evidence and favorable long‑term economics, while acknowledging short‑term expense pressures (operating expenses +$72.1M) and an operating loss of $106M that should narrow later in the year. Competitive risks, diagnostic supply issues, and the prior‑year milestone timing created some near‑term revenue volatility, but overall the company presented multiple tangible positives that outweigh the listed challenges.View all BBIO earnings summariesBBIO Stock 12 Month Forecast
Average Price Target
$107.29
▲(39.80% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Exelixis
―
Ionis Pharmaceuticals
―
Madrigal Pharmaceuticals
―
Moderna
―
Ownership Overview
13.45% Insiders
25.78% Mutual Funds
38.63% Other Institutional Investors
7.63% Public Companies and Individual Investors